New Research from the CWMH: Risk of Major Malformations in Infants with Prenatal Exposure to Benzodiazepines
Data from an ongoing pregnancy registry offers reassurance that benzodiazepines do not appear to have major teratogenic effects.
New Research from the CWMH: Gestational Weight Gain in Women Taking Second Generation Antipsychotics During Pregnancy
The use of the newer “atypical” or second-generation antipsychotic (SGA) agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. [...]
National Pregnancy Registry for Atypical Antipsychotics Milestone
We are excited to announce the enrollment of our 1000th participant in the National Pregnancy Registry for Atypical Antipsychotics! Formed in 2008, the Registry was established at MGH to prospectively evaluate the rates of [...]
Antipsychotics and Pregnancy Part 2: Preliminary Data from the MGH Pregnancy Registry
This is the second part of a two part series on the use of antipsychotic medications during pregnancy. Read Part 1 here, which reviews data from the Australian antipsychotic registry.
Antipsychotics and Pregnancy Part 1: Preliminary Data from the Australian Registry
This is the first part of a two part series on the use of antipsychotic medications during pregnancy. Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing [...]
The National Pregnancy Registry for Atypical Antipsychotics: Looking Ahead to 2012
We want to thank those of you who have continued to subscribe to our blog and who have visited our website. Some have written noting particular interest in the research conducted at the MGH Center for Women's Mental Health, including the National Pregnancy Registry for Atypical Antipsychotics.
In Utero Exposure to Antipsychotics
May 2011, ObGyn News, Lee S. Cohen, MD